Refractory Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) Alone and When Co-administered With Humanized Anti-CD19 Chimeric Antigen Receptor Redirected T Cells (huCART19) In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
Verified date | May 2024 |
Source | University of Pennsylvania |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single center, open-label, phase 1 study to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.
Status | Active, not recruiting |
Enrollment | 23 |
Est. completion date | January 2036 |
Est. primary completion date | January 2036 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1. Patients with relapsed or refractory B cell ALL: a. Patients with 2nd or greater relapse or refractory to 1st salvage as defined by: i. Recurrent disease in the bone marrow identified morphologically, by immunohistochemistry or by Flow cytometry. ii. Patients with extramedullary relapse only (no bone marrow involvement) will be eligible if disease response can be assessed radiographically b. Patients with refractory disease as defined by: i. Failure to achieve remission (<5% bone marrow blasts) after 2 cycles of induction chemotherapy ii. Patients that achieve remission but remain MRD+ after =2 cycles of induction chemotherapy. c. Patients with Ph+ ALL are eligible provided they are intolerant to or have failed tyrosine kinase inhibitor therapy. d. Patients with prior or current history of CNS3 disease* will be eligible only if CNS disease is responsive to therapy. i. *CNS disease definitions: 1. CNS1 - no blasts seen on cytocentrifuge (CNS negative); 2. CNS2 - total nucleated cell count <5x106/L, but blasts seen on cytocentrifuge; 3. CNS3 - total nucleated cell count 5x106/L with blasts on cytocentrifuge and/or signs of CNS leukemia (i.e. cranial nerve palsy). - 2. For Cohort 1: Documentation of CD22 expression on malignant cells at relapse. For Cohort 2: Documentation of CD22 and/or CD19 - 3. Adequate vital organ function defined as: 1. Creatinine = 1.6 mg/dl 2. ALT/AST = 3x upper limit of normal range 3. Total or Direct bilirubin = 2.0 mg/dl. If Total bilirubin is =2.0, Direct bilirubin does not need to be assessed. 4. Left Ventricle Ejection Fraction (LVEF) = 40% confirmed by ECHO/MUGA - 4. Male or female age = 18 years. - 5. ECOG Performance Status that is either 0 or 1. - 6. No contraindications for leukapheresis. - 7. Subjects of reproductive potential must agree to use acceptable birth control methods. Exclusion Criteria: - 1. Active hepatitis B or active hepatitis C. - 2. HIV Infection. - 3. Class III/IV cardiovascular disability according to the New York Heart Association Classification. - 4. Subjects with clinically apparent arrhythmia or arrhythmias who are not stable on medical management within two weeks of eligibility confirmation by physician-investigator. - 5. Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy. - 6. Planned concurrent treatment with systemic steroids or immunosuppressant medications. Patients may be on a stable low dose of steroids (<10mg equivalent of prednisone) for chronic respiratory conditions or adrenal insufficiency. For additional details regarding use of steroid and immunosuppressant medications. - 7. CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity. - 8. Pregnant or nursing (lactating) women. - 10. Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system. |
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess the safety of CART22-65s in ALL subjects using the common terminology criteria of adverse events (CTCAE) v5.0. | Frequency and severity of adverse events, including, but not limited to, cytokine release syndrome (CRS). | 15 months | |
Primary | Assess the safety of combination CART22-65s and huCART19 in relapsed/refractory ALL Subjects using the common terminology criteria of adverse events (CTCAE) v5.0. | Frequency and severity of adverse events, including, but not limited to, cytokine release syndrome (CRS). | 15 months | |
Secondary | Tumor response. | Overall Complete Remission Rate (ORR) at Day 28 which includes CR and CR with incomplete blood count recovery (CRi). | 28 Days | |
Secondary | Tumor response. | overall response rate (CR/CRi by or at Month 6) and disease response status at Month 6 | 6 months | |
Secondary | Tumor response. | overall survival (OS) | 1 Year | |
Secondary | Tumor response. | duration of remission (DOR) | 1 Year | |
Secondary | Tumor response. | relapse free survival (RFS) | 1 Year | |
Secondary | Tumor response. | event free survival (EFS) | 1 Year | |
Secondary | CAR T cell kinetics | Engraftment and persistence in blood by qPCR (or flow cytometry) | 1 Year | |
Secondary | CAR T cell kinetics | Trafficking to target tissue (bone marrow) or other tissues (cerebral spinal fluid and other tissues if available) as determined by qPCR (or flow cytometry). | 1 Year | |
Secondary | Evaluate bioactivity of CAR T cells | Measure levels of systemic soluble immune and inflammatory factors by Luminex-based analyses | 1 Year | |
Secondary | Determine antigen expression and normal B cell levels in response to CAR T cells | Measure CD22, CD19 and B cell levels pre- and post-CAR T cell infusion by flow cytometry | 1 Year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02551718 -
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
|
N/A | |
Recruiting |
NCT04888442 -
Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL
|
Phase 1 | |
Suspended |
NCT03128034 -
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03739606 -
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
|
Phase 2 | |
Recruiting |
NCT03241940 -
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT02146924 -
Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
|
Phase 1 | |
Recruiting |
NCT04000698 -
Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias
|
Phase 3 | |
Completed |
NCT03096782 -
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
|
Phase 2 | |
Completed |
NCT03575325 -
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
|
Phase 2 | |
Completed |
NCT04888468 -
Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
|
Phase 1 | |
Terminated |
NCT03094611 -
Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT02392572 -
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
|
Phase 1/Phase 2 | |
Recruiting |
NCT03263572 -
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT03519984 -
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
|
Phase 1 | |
Completed |
NCT04562792 -
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT01619761 -
NK Cells in Cord Blood Transplantation
|
Phase 1 | |
Completed |
NCT01865617 -
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT02727803 -
Personalized NK Cell Therapy in CBT
|
Phase 2 | |
Terminated |
NCT01620216 -
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
|
Phase 2 | |
Recruiting |
NCT04325841 -
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
|
Phase 2 |